사이클로스포린 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석(2025-2034년)

The Global Cyclosporine Market, valued at USD 3.3 billion in 2024, is expected to experience robust growth at a CAGR of 14.5% from 2025 to 2034. This impressive expansion is mainly driven by the rising demand for organ transplantation procedures, which depend on immunosuppressive therapies to prevent organ rejection. As more people undergo life-saving transplants, the need for cyclosporine to manage immune responses is increasing rapidly.

In addition to organ transplants, the market is being significantly influenced by the growing prevalence of autoimmune disorders such as rheumatoid arthritis, psoriasis, and autoimmune myasthenia gravis. Cyclosporine has proven to be an effective treatment option for managing these conditions, boosting its demand in the pharmaceutical industry. As healthcare access continues to improve in developing regions, more patients are being treated with cyclosporine, further accelerating its market growth. The global push toward increasing awareness of organ donation and the continuous advancements in transplant technologies are also contributing to the increasing usage of cyclosporine.

With a projected surge in R&D investments for advanced immunosuppressive therapies, the market is expected to expand rapidly in the coming years. The market is segmented by indication, including transplant rejection prophylaxis, autoimmune myasthenia gravis, rheumatoid arthritis, psoriasis, dry eye, and others. In 2024, transplant rejection prophylaxis held the largest share of the market, valued at USD 1.2 billion. This dominance is due to the critical role cyclosporine plays in preventing organ rejection, particularly in kidney, liver, and heart transplant patients. As transplant techniques improve and post-surgical care evolves, the demand for effective prophylactic treatments continues to rise.

When it comes to dosage forms, cyclosporine is available in eye drops, solutions, creams and ointments, and capsules. Capsules accounted for the largest market share in 2024, making up 31.8% of the total market. Their ease of use and effectiveness in long-term treatments, particularly for autoimmune diseases and organ transplants, make them the preferred form. Advances in encapsulation technologies have enhanced cyclosporine's bioavailability and stability, driving further growth in this segment.

The U.S. cyclosporine market, valued at USD 1.1 billion in 2024, stands as a leader due to its advanced healthcare system, high adoption rates of immunosuppressive treatments, and the widespread prevalence of chronic conditions like autoimmune disorders and the need for organ transplants. The presence of prominent industry players, coupled with continuous innovation and favorable reimbursement policies, creates a fertile environment for the sustained growth of the cyclosporine market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of autoimmune diseases
    • 3.2.1.2 Growing organ transplantation procedures
    • 3.2.1.3 Increase in potential clinical pipeline candidates
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Transplant rejection prophylaxis
• 5.3 Rheumatoid arthritis
• 5.4 Psoriasis
• 5.5 Autoimmune myasthenia gravis
• 5.6 Dry eye
• 5.7 Other indications

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Capsule
• 6.3 Eye drops
• 6.4 Solutions
• 6.5 Creams and ointments

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Parenteral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Avet Pharmaceuticals
• 10.2 AdvaCare Pharm
• 10.3 AbbVie
• 10.4 Apotex
• 10.5 Cipla
• 10.6 Dr. Reddy's Laboratories
• 10.7 Novartis
• 10.8 Santen Pharmaceutical
• 10.9 Sun Pharmaceutical Industries
• 10.10 Strides Pharma Science Limited
• 10.11 Teva Pharmaceutical Industries
• 10.12 Viatris